Child Growth Disorders — Short Stature, GHD & Treatment Guide — Symptoms, Causes & Treatment | MyMedicPlus

Growth disorders in children refer to conditions where a child grows significantly shorter, taller, or at a slower rate than expected for their age and sex. Short stature — height more than 2 standard deviations below the mean for age and sex — affects approximately 3% of all children. It can be a normal variant (familial short stature or constitutional delay of growth and puberty) or indicate an underlying pathological cause. Pathological causes include growth hormone deficiency (GHD), hypothyroidism, Turner syndrome, chronic illness (coeliac disease, inflammatory bowel disease, chronic kidney disease), and skeletal dysplasia. Early identification enables effective treatment. Growth disorders diagnosed early — before epiphyseal plate fusion at the end of puberty — allow effective treatment with the greatest height gain potential. Any child crossing more than two centile lines downward on serial growth charts over 6-12 months should be referred for paediatric endocrinology assessment without delay. The National Child Measurement Programme in the UK measures all children in reception (age 4-5) and Year 6 (age 10-11), providing systematic population-level growth surveillance.

Normal variants of short stature: familial short stature (parents are short — genetic potential); constitutional delay of growth and puberty (CDGP — 'late bloomer' — delayed bone age with later growth spurt, more common in boys). Pathological causes: growth hormone deficiency (GHD) — most common treatable hormonal cause; may be isolated (idiopathic or genetic mutations in GH1, GHRHR) or associated with other pituitary hormone deficiencies (craniopharyngioma, cranial irradiation, brain tumour, pituitary trauma); hypothyroidism (Hashimoto's thyroiditis); Turner syndrome (45,X0 — affects girls, associated with short stature and gonadal dysgenesis); small for gestational age (SGA) without catch-up growth; Noonan syndrome; Prader-Willi syndrome; chronic systemic illness; and nutritional deficiencies.

Short stature: height below -2 SD (below the 3rd centile on growth chart) or declining centiles on serial measurements. Growth velocity: growth velocity below 25th centile for age is a more sensitive indicator of growth disorder than absolute height — regular measurement at 6-12 month intervals is essential. Associated symptoms: delayed puberty (GHD, Turner syndrome, Noonan syndrome); mid-face hypoplasia and frontal bossing (GHD); webbed neck, widely spaced nipples (Turner syndrome); coarsening of facial features and goitre (hypothyroidism); and symptoms of the underlying condition (pallor for coeliac disease, abdominal symptoms). Tall stature in boys should prompt assessment for Klinefelter syndrome (47,XXY) or growth hormone excess (pituitary tumour).

Accurate serial height and weight measurements plotted on appropriate growth charts (UK WHO charts, or Turner-specific charts) are fundamental. Mid-parental height calculation establishes genetic height potential. Bone age X-ray (left hand and wrist — Greulich-Pyle or Tanner-Whitehouse method) compares skeletal maturation with chronological age; delayed bone age suggests CDGP or GHD; advanced bone age indicates early puberty or excess androgens. Investigations: IGF-1 (insulin-like growth factor 1) and IGFBP-3 (low in GHD); thyroid function tests; full blood count, ESR, CRP; renal function; coeliac serology (anti-tTG IgA); karyotype (in girls — Turner syndrome). Growth hormone stimulation tests (arginine, glucagon, insulin tolerance test) confirm GHD if IGF-1 is low. MRI pituitary gland in confirmed GHD.

Growth hormone deficiency: recombinant human growth hormone (somatropin) injections — subcutaneous, daily, self-administered by parents or children. Treatment is highly effective: improves height by 1-2 SD over untreated height prediction and significantly improves final adult height. Initiated as early as possible before epiphyseal closure (puberty). GH therapy also approved in Turner syndrome, Noonan syndrome, SGA without catch-up, Prader-Willi syndrome, chronic kidney disease, and idiopathic short stature in some countries. Hypothyroidism: levothyroxine replacement restores normal growth. Coeliac disease: strict gluten-free diet achieves catch-up growth. Constitutional delay: often reassurance suffices; low-dose sex hormone therapy (testosterone or oestrogen) can induce puberty if significantly delayed and psychologically distressing. Turner syndrome: oestrogen replacement for puberty induction (from age 11-12 years). Lonapegsomatropin (TransCon hGH) — a weekly prodrug formulation of growth hormone — offers equivalent efficacy to daily somatropin injections in a once-weekly injection, improving adherence and convenience for children and families. Vosoritide, a CNP analogue targeting FGFR3 signalling, is approved for achondroplasia in children aged 2 and above and increases annualised growth velocity by approximately 1.6 cm/year.

Untreated growth hormone deficiency results in significantly reduced adult height — often 4-6 cm below genetic potential. Adult GHD (after epiphyseal fusion) causes: reduced muscle mass and strength, increased body fat (central obesity), reduced bone mineral density (osteoporosis), adverse cardiovascular risk profile (dyslipidaemia, increased intima-media thickness), fatigue, reduced quality of life, and psychological impact (social adjustment difficulties, depression). Turner syndrome without GH treatment results in an average adult height of 143-147 cm. Untreated hypothyroidism in childhood causes growth failure, developmental delay, and cognitive impairment. Delayed diagnosis of growth disorders misses the optimal treatment window before epiphyseal closure.

There is no prevention for most growth disorders, but early recognition is critical. Primary care practitioners should plot height and weight on standardised growth charts at every well-child check. Any child whose height centile drops across two major centile lines or whose growth velocity is below the 25th centile for age should be referred to a paediatric endocrinologist. Ensure adequate nutritional intake — malnutrition is the most common cause of growth failure worldwide. Treat underlying conditions (coeliac disease, IBD, renal disease) to enable catch-up growth. Good sleep hygiene supports growth hormone secretion (GH is released predominantly during deep sleep). Provide psychosocial support for children with short stature — they may face teasing and social difficulties.

Refer to a paediatric endocrinologist if your child's height is below the 0.4th centile (below -2.67 SD on the growth chart); if the child is growing significantly below their expected mid-parental height centile (calculated from parents' heights); if growth velocity drops across two or more centile lines between measurements taken 6–12 months apart; or if puberty is significantly delayed (no breast development by age 13 in girls; no testicular enlargement by age 14 in boys). See a GP promptly if a previously well-growing child stops gaining height or loses weight unexpectedly — this may indicate undiagnosed coeliac disease, inflammatory bowel disease, or an endocrine condition. Ensure routine health checks include plotting height and weight on standardised growth charts — declining centiles detected early allow treatment before epiphyseal closure. Any child with headaches, visual problems, and growth failure should be urgently evaluated for a pituitary tumour (craniopharyngioma).